Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARV-6723 + pembrolizumab
- Development stage
- Phase 2
- Lead developer
- Arvinas
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
ARV-6723 + pembrolizumab is an investigational combination regimen consisting of ARV-6723, an orally bioavailable proteolysis-targeting chimera (PROTAC) designed to degrade hematopoietic progenitor kinase 1 (HPK1), and pembrolizumab (Keytruda), an intravenous or subcutaneous anti-programmed cell death protein 1 (PD-1) monoclonal antibody. HPK1 is a key negative regulator of immune activation expressed across various immune cells, including T cells, B cells, natural killer cells, and dendritic cells. By degrading HPK1, ARV-6723 removes both its kinase-dependent and kinase-independent scaffolding functions, potentially reversing immune suppression in the tumor microenvironment. Pembrolizumab blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby unleashing T-cell-mediated antitumor activity. The combination of these two immunotherapies is designed to synergistically enhance immune activation and overcome resistance to checkpoint inhibition. Developed by Arvinas, the combination is being evaluated in a Phase 1/2 clinical trial (NCT07749586) for the treatment of patients with advanced solid tumors.
- Other names
- ARV-6723 + KeytrudaARV-6723 and pembrolizumabARV6723 and pembrolizumabARV 6723 and pembrolizumabARV6723 + pembrolizumabpembrolizumab + ARV-6723
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)MAP4K1 (Hematopoietic progenitor kinase 1)
Beyond the preview
Go deeper on ARV-6723 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARV-6723 + pembrolizumab.